Showing results (101-110 of 871) with videos related to
Sort By:
Pageof 88
Molecular and Cellular Endocrinology|May 1, 1983
Effect of prolactin, testosterone and estrogen on prolactin binding in the rat testis, prostate, seminal vesicle and liverT Amit, R J Barkey, M B YoudimEuropean Journal of Pharmacology|September 24, 1981
Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in ratsM B Youdim, S Yehuda, Y Ben-UriahJournal of Neural Transmission. Supplementum|January 1, 1992
Neurotoxicity and neuroprotection in Parkinson's diseaseK W Lange, M B Youdim, P RiedererClinical Pharmacology and Therapeutics|December 1, 1994
Biochemical actions of l-deprenyl (selegiline)K W Lange, P Riederer, M B YoudimBritish Journal of Pharmacology|July 1, 1983
Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blockerR Ashkenazi, J P Finberg, M B YoudimActa Neurologica Scandinavica. Supplementum|January 1, 1989
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?M B Youdim, D Ben-Shachar, P RiedererAdvances in Neurology|January 1, 1993
Recent advances in pharmacological therapy of Parkinson's diseaseP Riederer, K W Lange, M B YoudimBritish Journal of Pharmacology|February 1, 1975
Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancyS Parvez, S H Parvez, M B YoudimBritish Journal of Pharmacology|February 13, 2001
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BM B Youdim, A Gross, J P FinbergEuropean Neurology|January 1, 1991
Iron in brain function and dysfunction with emphasis on Parkinson's diseaseM B Youdim, D Ben-Shachar, P RiedererPageof 88